Receptor targets compound properties

Donepazil is a reasonably potent D4 dopamine receptor inverse agonist (/targeted compounds with improved D2 potency, while maintaining suitable properties for CNS activity. This resulted in a series of isoindoles from which eight compounds were synthesized and tested, leading to measured D2 receptor affinities between 156 and 1700 nM. These included compound 3, shown in Figure 15.9, which was also shown to penetrate the brain in vivo. 

Abstract The entry of viruses into target cells involves a complex series of sequential steps, with opportunities for inhibition at every stage. Entry inhibitors exert their biological properties by inhibiting protein-protein interactions either within the viral envelope (Env) glycoproteins or between viral Env and host-cell receptors. The nature of resistance to entry inhibitors also differs from compounds inhibiting enzymatic targets due to their different modes of action and the relative variability in... 

There are a variety of structural classes of compounds that are active against each phosphodiesterase, and evidence suggests that selective inhibitors of PDEs can be identified. The structural diversity of PDE inhibitors provides a multitude of opportunities for development of compounds with drug-like properties. Furthermore, phosphodiesterase inhibition, which avoids direct interaction of a compound with a cell surface or nuclear receptor, may circumvent some of the target selectivity issues that can complicate receptor-based therapeutic approaches. As noted above, the specific subcellular distribution of phosphodiesterase enzymes is a key feature of their ability to modulate intracellular signaling pathways. This localization of the enzyme may minimize non-specific target... 

Figure 2.11 Plot of compounds developed for different target classes based on a principal components analysis (PCA) of 2D structure-based property fingerprints. Compounds are coded according to their target class (triangle, PDE square, 5HT receptor diamond, statin circle, F-quinoline antibiotics) and clinical status at the time (gray, ok yellow, clearance issue red,...

---